Your institution may have access to this item. Find your institution then sign in to continue.
Title
Fast track.
Abstract
Reports that the U.S. Food and Drug Administration has designated Tarceva developed by Melville, New York-based OSI Pharmaceuticals Inc. as a fast-track product for treatment of patients with advanced lung cancer.